Want to see GRCE full AI Analyst Report?
Top Page
Grace Therapeutics
(NASDAQ:GRCE)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.00
▼(-14.16% Downside)
Action:Reiterated
Date:07/30/26
The score is primarily constrained by pre-commercial fundamentals (no revenue, ongoing losses and negative free cash flow) and weak technical positioning (trading below all key moving averages). Low leverage and improving loss/cash burn trends provide some support but do not offset the continued need for external funding.
Positive Factors
Conservative balance sheet / low leverage
Essentially no debt and roughly $64M of equity in 2026 materially reduce refinancing and interest risks. This financial flexibility supports remediation, regulatory activities, and technology transfer efforts without immediate dependence on dilutive financing, improving the company’s ability to execute near-term development milestones.
Negative Factors
Pre-commercial: zero revenue
The company has recorded no commercial revenue for multiple years, meaning value realization depends entirely on successful NDA resubmission and eventual market launch. Absent commercialization, the firm lacks operating cash generation, making long-term scalability and profitability contingent on execution and approval outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Essentially no debt and roughly $64M of equity in 2026 materially reduce refinancing and interest risks. This financial flexibility supports remediation, regulatory activities, and technology transfer efforts without immediate dependence on dilutive financing, improving the company’s ability to execute near-term development milestones.
Read all positive factors
Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.85M
Dividend YieldN/A
Average Volume (3M)58.56K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS Growth43.67%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding16,274,027
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.84K
Enterprise Value/Ebitda-1.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Grace Therapeutics Business Overview & Revenue Model
Company Description
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is G...
How the Company Makes Money
null...
Grace Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.07M | -23.74M | -15.37M | -24.51M | -19.17M |
| Net Income | -7.79M | -13.63M | -17.44M | -57.39M | -12.27M |
Balance Sheet | |||||
| Total Assets | 66.65M | 71.99M | 73.30M | 79.12M | 128.62M |
| Cash, Cash Equivalents and Short-Term Investments | 16.98M | 22.13M | 23.00M | 27.89M | 43.66M |
| Total Debt | 0.00 | 0.00 | 0.00 | 485.00K | 295.00K |
| Total Liabilities | 2.76M | 5.38M | 11.56M | 11.17M | 20.35M |
| Stockholders Equity | 63.90M | 66.61M | 61.74M | 67.95M | 108.27M |
Cash Flow | |||||
| Free Cash Flow | -8.87M | -14.90M | -12.36M | -15.93M | -17.23M |
| Operating Cash Flow | -8.87M | -14.90M | -12.33M | -15.91M | -17.23M |
| Investing Cash Flow | 0.00 | 0.00 | 104.00K | 13.15M | -3.52M |
| Financing Cash Flow | 3.71M | 14.03M | 7.36M | 304.00K | 0.00 |
Grace Therapeutics Technical Analysis
Negative
2.33
Price Trends
2.35
Negative
2.96
Negative
3.20
Negative
Market Momentum
>-0.01
Positive
43.93
Neutral
14.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.35, and below the 200-day MA of 3.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.93 is Neutral, neither overbought nor oversold. The STOCH value of 14.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRCE.
Grace Therapeutics Risk Analysis
Grace Therapeutics disclosed 53 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We face risks related to the growth of artificial intelligence and data analytics. Q1, 2026
2.
We received a Complete Response Letter (CRL) from the FDA citing certain manufacturing deficiencies and other non-clinical issues, which may delay or prevent approval of GTx-104. Q1, 2026
3.
If our current CMO is unable to timely resolve the deficiencies identified by the FDA in the CRL related to GTx-104, we may be required to engage an alternative manufacturer, which could result in significant delays, increased costs, or our inability to obtain regulatory approval or commercialize GTx-104 at all. Q1, 2026
Grace Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $77.86M | -1.96 | -241.96% | ― | ― | 55.59% | |
53 Neutral | $51.71M | -3.72 | 76.02% | ― | ― | -13.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $26.30M | -0.49 | -139.47% | ― | 43.88% | 14.79% | |
43 Neutral | $33.85M | -4.05 | -14.15% | ― | ― | 43.67% | |
43 Neutral | $6.10M | -0.36 | -333.32% | ― | ― | 39.14% |
* Healthcare Sector Average
GRCE
Grace Therapeutics
2.07
-0.82
-28.37%
PYPD
PolyPid
4.37
1.01
30.06%
ALGS
Aligos Therapeutics
4.32
-2.96
-40.66%
INKT
MiNK Therapeutics
10.59
-4.57
-30.15%
CVKD
Cadrenal Therapeutics, Inc.
2.09
-8.33
-79.94%
Grace Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics advances dual-source manufacturing for GTx-104
Neutral
Jul 28, 2026
On July 28, 2026, Grace Therapeutics announced it had received formal minutes from an FDA Type A meeting held to discuss the Complete Response Letter issued on April 23, 2026 for its GTx-104 new drug application. The CRL focused on facility-level ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
Neutral
Jun 18, 2026
On June 18, 2026, Grace Therapeutics updated its corporate presentation to highlight progress on GTx-104, an intravenous nimodipine designed to address limitations of long-established oral standard-of-care therapy in aneurysmal subarachnoid hemorr...
Executive/Board Changes
Grace Therapeutics VP of Clinical Operations Departs Role
Neutral
Jun 5, 2026
Grace Therapeutics, Inc. reported that Vice President of Clinical Operations Carrie D’Andrea will leave her executive role and cease to be an employee effective June 5, 2026, following board approval on June 1, 2026. She is expected to recei...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.